Monitoring Report: Viral Gastroenteritis - April 2024 Data

Samuel Gratzl, PhD

Brianna M Goodwin Cartwright, MS

Patricia J Rodriguez, PhD, MPH

Charlotte Baker, DrPH, MPH, CPH

Duy Do, PhD

Nicholas L Stucky, MD, PhD

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:

Dr Nicholas Stucky
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with viral gastroenteritis. This study provides current hospitalization trends associated with two common viruses causing gastroenteritis: norovirus and rotavirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through April 30, 2024) overall and for each virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and April 30, 2024. We identified people who tested positive for each virus within 14 days of the hospitalization. We report monthly trends in the rate of hospitalizations associated with each virus per all hospitalizations and test positivity for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 5,533 hospitalizations of 5,424 unique patients who tested positive for a monitored virus between October 01, 2019 and April 30, 2024. Additionally, we included 238,344 lab results across 113,219 unique patients of which 10,811 were positive between October 01, 2019 and April 30, 2024.

Hospitalizations associated with these norovirus and rotavirus accounted for 0.21% of all hospitalizations in April 2024 (+5.4% from March 2024). The combined test positivity rate of these two enteric viruses was 8.4% in April 2024. For the population between age 0-4 years old, the hospitalizations associated with these two enteric viruses accounted for 0.13% of all hospitalizations in April (+11.5% from March 2024). The enteric virus test positivity rate was 18.4% for the month of April in this age group. In the population over 65 years of age, hospitalizations associated with these enteric viruses accounted for 0.22% of all hospitalizations in April 2024 (-4.8% from March 2024). The enteric virus test positivity rate was 6.0% for the month of April in this age group.

Discussion: We see evidence that we are in the peak of the norovirus and rotavirus season. The overall timeseries trends of hospitalizations associated with these viruses show a steady increase over the last months, leading to a rate of 0.21% in April 2024 in the overall population. Similar trends can be observed in test positivity rates and the two high-risk sub populations: infants and children and older adults.

In the overall and adult over age 65 population, norovirus causes 2 to 3 times higher hospitalization rates than rotavirus. However, in the population of infants and children, both viruses have similar hospitalization rates. We will continue to monitor trends of norovirus- and rotavirus-associated hospitalizations and their test positivity.

Trends in Surveillance

Overall population



	Overall	norovirus	rotavirus
March 01, 2024	0.20%	0.15%	0.06%
April 01, 2024	0.21%	0.15%	0.06%
Change (percentage)	+5.4%	+0.1%	+12.8%
Difference (percentage points)	+0.0%	+0.0%	+0.0%



	Overall	norovirus	rotavirus
March 01, 2024	8.4%	12.3%	4.5%
April 01, 2024	8.4%	12.0%	4.9%
Change (percentage)	+0.2%	-2.5%	+8.1%
Difference (percentage points)	+0.0%	-0.3%	+0.4%

Overall, the rate of hospitalizations associated with these two enteric viruses increased from March to April (+5.4%). Norovirus-related hospitalizations were unchanged (+0.1%), while rotavirus-related hospitalizations increased by 12.8%. Combined hospitalizations associated with these enteric viruses accounted for 0.21% of all hospitalizations in April.

The combined test positivity rate of these two enteric viruses was 8.4% and was unchanged from March to April (no change when comparing the two months). Norovirus test positivity rate decreased by 2.5%, while rotavirus test positivity rate increased by 8.1%.

Infants and children (age 0-4)



	Overall	norovirus	rotavirus
March 01, 2024	0.12%	0.06%	0.06%
April 01, 2024	0.13%	0.06%	0.07%
Change (percentage)	+11.5%	+6.4%	+16.1%
Difference (percentage points)	+0.0%	+0.0%	+0.0%



	Overall	norovirus	rotavirus
March 01, 2024	22.0%	27.4%	17.0%
April 01, 2024	18.4%	18.6%	18.3%
Change (percentage)	−16.4%	−32.3%	+7.4%
Difference (percentage points)	−3.6%	−8.9%	+1.3%

For the population between age 0-4 years old, the rate of hospitalizations associated with these two enteric viruses increased from March to April (+11.5%). Both norovirus- and rotavirus-related hospitalizations increased (+6.4% and +16.1% respectively). Combined hospitalizations associated with these enteric viruses accounted for 0.13% of all hospitalizations in April in this age group.

For this population, the enteric virus test positivity rate decreased from March to April (-16.4% change). Norovirus test positivity rate decreased by 32.3%, while rotavirus test positivity rate increased by 7.4%. The enteric virus test positivity rate was 18.4% for the month of April in this age group.

Older adults (age 65 and over)



	Overall	norovirus	rotavirus
March 01, 2024	0.23%	0.18%	0.06%
April 01, 2024	0.22%	0.15%	0.07%
Change (percentage)	−4.8%	−15.9%	+21.1%
Difference (percentage points)	−0.0%	−0.0%	+0.0%



	Overall	norovirus	rotavirus
March 01, 2024	5.9%	8.9%	3.0%
April 01, 2024	6.0%	8.8%	3.4%
Change (percentage)	+2.0%	−1.5%	+13.1%
Difference (percentage points)	+0.1%	−0.1%	+0.4%

In the population over 65 years of age, there was a 4.8% decrease in the rate of hospitalizations associated with these two enteric viruses from March to April. Norovirus-related hospitalizations decreased (-15.9%), while rotavirus-related hospitalizations increased 21.1%. Combined hospitalizations associated with these enteric viruses accounted for 0.22% of all hospitalizations in April in this age group.

For this population, the enteric virus test positivity rate increased from March to April (+2.0% change). Norovirus test positivity rate decreased by 1.5%, while rotavirus test positivity rate increased by 13.1%. The enteric virus test positivity rate was 6.0% for the month of April in this age group.

Introduction

Norovirus and rotavirus are significant contributors to gastrointestinal infections worldwide, imposing substantial burdens on populations and healthcare systems (Troeger 2018, Ahmed 2014, Lopman 2011). In the United States, norovirus and rotavirus infections collectively account for a considerable proportion of hospitalizations related to gastrointestinal illnesses (Lopman 2011), underscoring the importance of comprehensively understanding the trends in viral infections affecting

public health. Like their respiratory counterparts, norovirus and rotavirus infections pose particular risks to vulnerable populations, including infants, children, and older adults (Ahmed et al., 2014). Despite the focus on pediatric populations due to the severity of symptoms and potential complications, older adults also face significant risks of hospitalization and mortality from these viral infections (Anderson 2004). Severe outcomes and prolonged illness durations are particularly prevalent among the elderly. For hospitalized individuals who are immunocompromised or suffer from significant medical comorbidities, enteric virus infections can directly contribute to extended hospital stays, heightened medical complexities, and, in rare instances, mortality. These details highlight the interaction between viral infections and underlying health conditions.

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted. This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated viral gastroenteritis-associated hospitalization trends of two common viruses causing gastroenteritis – norovirus and rotavirus – between October 01, 2019 and April 30, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., norovirus tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on May 14, 2024 and included de-identified patient care data primarily located across ten states: Arizona, California, Florida, Hawaii, Kansas, Louisiana, North Carolina, Texas, Washington, and Wisconsin.

Population

We identified hospitalized patients who tested positive for one of the selected viruses causing gastroenteritis within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every viral gastroenteritis-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once.

In addition, we identified all lab results for one of the selected viruses and calculated the test positivity rate per month.

Hospitalization rate analysis

Characteristics of viral gastroenteritis-associated hospitalized patients were summarized, including demographics and comorbidities by year. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Viral gastroenteritis-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated monthly as the number of patients with a viral gastroenteritis associated hospitalization divided by the number of patients with a hospital admission in that month. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of lab results with positive results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 5,533 hospitalizations of 5,424 unique patients (Table 1).

Table 1: Patient characteristics by year.

	2019	2020	2021	2022	2023	2024	Overall
N	167 (100.00%)	251 (100.00%)	488 (100.00%)	1,233 (100.00%)	2,219 (100.00%)	1,066 (100.00%)	5,424 (100.00%)
Age Group							
< 6 months	n/a	n/a	13 (2.66%)	27 (2.19%)	29 (1.31%)	16 (1.50%)	95 (1.75%)
6 - <12 months	n/a	n/a	17 (3.48%)	19 (1.54%)	39 (1.76%)	17 (1.59%)	99 (1.83%)
1 - <2 years	n/a	n/a	19 (3.89%)	37 (3.00%)	44 (1.98%)	15 (1.41%)	126 (2.32%)
2 - 4 years	n/a	n/a	15 (3.07%)	31 (2.51%)	55 (2.48%)	25 (2.35%)	133 (2.45%)
5 - 17 years	n/a	n/a	14 (2.87%)	34 (2.76%)	60 (2.70%)	44 (4.13%)	161 (2.97%)
18 - 49 years	38 (22.75%)	46 (18.33%)	118 (24.18%)	270 (21.90%)	542 (24.43%)	288 (27.02%)	1,302 (24.00%)
50 - 64 years	45 (26.95%)	60 (23.90%)	106 (21.72%)	259 (21.01%)	474 (21.36%)	190 (17.82%)	1,134 (20.91%)
65 - 74 years	23 (13.77%)	43 (17.13%)	73 (14.96%)	242 (19.63%)	416 (18.75%)	170 (15.95%)	967 (17.83%)
75 - 84 years	32 (19.16%)	47 (18.73%)	78 (15.98%)	196 (15.90%)	359 (16.18%)	194 (18.20%)	906 (16.70%)
85+ years	15 (8.98%)	25 (9.96%)	35 (7.17%)	118 (9.57%)	201 (9.06%)	107 (10.04%)	501 (9.24%)
Sex							
Female	92 (55.09%)	120 (47.81%)	245 (50.20%)	652 (52.88%)	1,195 (53.85%)	570 (53.47%)	2,874 (52.99%)
Male	75 (44.91%)	130 (51.79%)	236 (48.36%)	574 (46.55%)	1,003 (45.20%)	490 (45.97%)	2,508 (46.24%)
Unknown	n/a	n/a	n/a	n/a	21 (0.95%)	n/a	42 (0.77%)
Race							
White	123 (73.65%)	173 (68.92%)	337 (69.06%)	949 (76.97%)	1,607 (72.42%)	759 (71.20%)	3,948 (72.79%)
Black or African American	21 (12.57%)	41 (16.33%)	64 (13.11%)	111 (9.00%)	226 (10.18%)	121 (11.35%)	584 (10.77%)
Asian	n/a	n/a	12 (2.46%)	17 (1.38%)	41 (1.85%)	15 (1.41%)	93 (1.71%)
Native Hawaiian or Other Pacific Islander	n/a	n/a	n/a	n/a	16 (0.72%)	n/a	29 (0.53%)
American Indian or Alaska Native	n/a	n/a	n/a	10 (0.81%)	14 (0.63%)	n/a	34 (0.63%)
Other Race	13 (7.78%)	20 (7.97%)	59 (12.09%)	101 (8.19%)	247 (11.13%)	128 (12.01%)	568 (10.47%)
Declined to answer	n/a	n/a	n/a	n/a	13 (0.59%)	10 (0.94%)	32 (0.59%)
Unknown	n/a	n/a	11 (2.25%)	29 (2.35%)	50 (2.25%)	19 (1.78%)	136 (2.51%)

Ethnicity							
Hispanic or Latino	22 (13.17%)	30 (11.95%)	90 (18.44%)	187 (15.17%)	439 (19.78%)	220 (20.64%)	988 (18.22%)
Not Hispanic or Latino	136 (81.44%)	202 (80.48%)	372 (76.23%)	975 (79.08%)	1,682 (75.80%)	812 (76.17%)	4,179 (77.05%)
Declined to answer	n/a	n/a	n/a	n/a	11 (0.50%)	n/a	29 (0.53%)
Unknown	n/a	17 (6.77%)	24 (4.92%)	65 (5.27%)	87 (3.92%)	26 (2.44%)	228 (4.20%)
Virus							
norovirus	152 (91.02%)	211 (84.06%)	402 (82.38%)	902 (73.15%)	1,769 (79.72%)	787 (73.83%)	4,223 (77.86%)
rotavirus	15 (8.98%)	40 (15.94%)	86 (17.62%)	331 (26.85%)	450 (20.28%)	279 (26.17%)	1,201 (22.14%)

Hospitalization rate over time

The rate of viral gastroenteritis-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of monthly viral gastroenteritis-associated hospitalizations compared to all hospital admissions since October 2019



Figure 2: Rate of monthly viral gastroenteritis-associated hospitalizations compared to all hospital admissions since October 2019



Test positivity rate over time

We included 238,344 lab results with a known result of which 10,811 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Monthly test positivity rate since October 2019



Norovirus

Our norovirus study population consists of 4,274 hospitalizations of 4,223 unique patients (Table 2).

Table 2: Norovirus patient characteristics by year.

	2019	2020	2021	2022	2023	2024	Overall
N	152 (100.00%)	211 (100.00%)	402 (100.00%)	902 (100.00%)	1,769 (100.00%)	787 (100.00%)	4,223 (100.00%)
Age Group							
< 6 months	n/a	n/a	n/a	16 (1.77%)	13 (0.73%)	n/a	43 (1.02%)
6 - <12 months	n/a	n/a	14 (3.48%)	14 (1.55%)	23 (1.30%)	11 (1.40%)	65 (1.54%)
1 - <2 years	n/a	n/a	13 (3.23%)	24 (2.66%)	31 (1.75%)	n/a	78 (1.85%)
2 - 4 years	n/a	n/a	n/a	15 (1.66%)	28 (1.58%)	10 (1.27%)	64 (1.52%)
5 - 17 years	n/a	n/a	n/a	23 (2.55%)	36 (2.04%)	29 (3.68%)	103 (2.44%)
18 - 49 years	37 (24.34%)	43 (20.38%)	111 (27.61%)	219 (24.28%)	459 (25.95%)	231 (29.35%)	1,100 (26.05%)
50 - 64 years	43 (28.29%)	52 (24.64%)	89 (22.14%)	189 (20.95%)	380 (21.48%)	138 (17.53%)	891 (21.10%)
65 - 74 years	21 (13.82%)	37 (17.54%)	58 (14.43%)	169 (18.74%)	331 (18.71%)	131 (16.65%)	747 (17.69%)
75 - 84 years	31 (20.39%)	42 (19.91%)	66 (16.42%)	149 (16.52%)	302 (17.07%)	142 (18.04%)	732 (17.33%)
85+ years	14 (9.21%)	22 (10.43%)	32 (7.96%)	84 (9.31%)	166 (9.38%)	82 (10.42%)	400 (9.47%)
Sex							
Female	88 (57.89%)	104 (49.29%)	203 (50.50%)	486 (53.88%)	966 (54.61%)	419 (53.24%)	2,266 (53.66%)
Male	64 (42.11%)	106 (50.24%)	192 (47.76%)	413 (45.79%)	785 (44.38%)	363 (46.12%)	1,923 (45.54%)
Unknown	n/a	n/a	n/a	n/a	18 (1.02%)	n/a	34 (0.81%)
Race							
White	113 (74.34%)	150 (71.09%)	282 (70.15%)	701 (77.72%)	1,303 (73.66%)	580 (73.70%)	3,129 (74.09%)
Black or African American	19 (12.50%)	39 (18.48%)	57 (14.18%)	80 (8.87%)	181 (10.23%)	83 (10.55%)	459 (10.87%)

Asian	n/a	n/a	n/a	13 (1.44%)	30 (1.70%)	10 (1.27%)	67 (1.59%)
Native Hawaiian or Other Pacific Islander	n/a	n/a	n/a	n/a	n/a	n/a	12 (0.28%)
American Indian or Alaska Native	n/a	n/a	n/a	n/a	11 (0.62%)	n/a	24 (0.57%)
Other Race	12 (7.89%)	12 (5.69%)	41 (10.20%)	72 (7.98%)	188 (10.63%)	92 (11.69%)	417 (9.87%)
Declined to answer	n/a	n/a	n/a	n/a	10 (0.57%)	n/a	22 (0.52%)
Unknown	n/a	n/a	n/a	19 (2.11%)	37 (2.09%)	11 (1.40%)	93 (2.20%)
Ethnicity							
Hispanic or Latino	17 (11.18%)	21 (9.95%)	62 (15.42%)	128 (14.19%)	333 (18.82%)	145 (18.42%)	706 (16.72%)
Not Hispanic or Latino	126 (82.89%)	174 (82.46%)	317 (78.86%)	720 (79.82%)	1,361 (76.94%)	620 (78.78%)	3,318 (78.57%)
Declined to answer	n/a	n/a	n/a	n/a	n/a	n/a	21 (0.50%)
Unknown	n/a	14 (6.64%)	21 (5.22%)	49 (5.43%)	67 (3.79%)	18 (2.29%)	178 (4.22%)

Hospitalization rate over time

The rate of norovirus-associated hospitalization is shown in Figure 4. Figure 5 shows yearly trends.

Figure 4: Rate of monthly norovirus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 6: Rate of monthly norovirus-associated hospitalizations compared to all hospital admissions by year



Test positivity rate over time

We included 115,747 Norovirus lab results with a known result of which 8,047 were positive. The Norovirus test positivity rate is shown in Figure 7. Figure 8 shows yearly trends.

Figure 7: Monthly Norovirus test positivity rate since October 2019



Figure 9: Monthly Norovirus test positivity rate by year



Rotavirus

Our rotavirus study population consists of 1,259 hospitalizations of 1,201 unique patients (Table 3).

Table 3: Rotavirus patient characteristics by year.

	2019	2020	2021	2022	2023	2024	Overall
N	15 (100.00%)	40 (100.00%)	86 (100.00%)	331 (100.00%)	450 (100.00%)	279 (100.00%)	1,201 (100.00%)
Age Group							
< 6 months	n/a	n/a	n/a	11 (3.32%)	16 (3.56%)	n/a	52 (4.33%)
6 - <12 months	n/a	n/a	n/a	n/a	16 (3.56%)	n/a	34 (2.83%)
1 - <2 years	n/a	n/a	n/a	13 (3.93%)	13 (2.89%)	n/a	48 (4.00%)
2 - 4 years	n/a	n/a	n/a	16 (4.83%)	27 (6.00%)	15 (5.38%)	69 (5.75%)
5 - 17 years	n/a	n/a	n/a	11 (3.32%)	24 (5.33%)	15 (5.38%)	58 (4.83%)
18 - 49 years	n/a	n/a	n/a	51 (15.41%)	83 (18.44%)	57 (20.43%)	202 (16.82%)
50 - 64 years	n/a	n/a	17 (19.77%)	70 (21.15%)	94 (20.89%)	52 (18.64%)	243 (20.23%)
65 - 74 years	n/a	n/a	15 (17.44%)	73 (22.05%)	85 (18.89%)	39 (13.98%)	220 (18.32%)

75 - 84 years	n/a	n/a	12 (13.95%)	47 (14.20%)	57 (12.67%)	52 (18.64%)	174 (14.49%)
85+ years	n/a	n/a	n/a	34 (10.27%)	35 (7.78%)	25 (8.96%)	101 (8.41%)
Sex							
Female		n/a	16 (40.00%)	42 (48.84%)	166 (50.15%)	229 (50.89%)	151 (54.12%)	608 (50.62%)
Male		11 (73.33%)	24 (60.00%)	44 (51.16%)	161 (48.64%)	218 (48.44%)	127 (45.52%)	585 (48.71%)
Unknown		n/a	n/a	n/a	n/a	n/a	n/a	n/a
Race								
White		10 (66.67%)	23 (57.50%)	55 (63.95%)	248 (74.92%)	304 (67.56%)	179 (64.16%)	819 (68.19%)
Black or African American		n/a	n/a	n/a	31 (9.37%)	45 (10.00%)	38 (13.62%)	125 (10.41%)
Asian		n/a	n/a	n/a	n/a	11 (2.44%)	n/a	26 (2.16%)
Native Hawaiian or Other Pacific Islander		n/a	n/a	n/a	n/a	11 (2.44%)	n/a	17 (1.42%)
American Indian or Alaska Native		n/a	n/a	n/a	n/a	n/a	n/a	10 (0.83%)
Other Race		n/a	n/a	18 (20.93%)	29 (8.76%)	59 (13.11%)	36 (12.90%)	151 (12.57%)
Declined to answer		n/a	n/a	n/a	n/a	n/a	n/a	10 (0.83%)
Unknown		n/a	n/a	n/a	10 (3.02%)	13 (2.89%)	n/a	37 (3.08%)
Ethnicity								
Hispanic or Latino		n/a	n/a	28 (32.56%)	59 (17.82%)	106 (23.56%)	75 (26.88%)	282 (23.48%)
Not Hispanic or Latino		10 (66.67%)	28 (70.00%)	55 (63.95%)	255 (77.04%)	321 (71.33%)	192 (68.82%)	861 (71.69%)
Declined to answer		n/a	n/a	n/a	n/a	n/a	n/a	n/a
Unknown		n/a	n/a	n/a	16 (4.83%)	20 (4.44%)	n/a	50 (4.16%)

Hospitalization rate over time

The rate of rotavirus-associated hospitalization is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Rate of monthly rotavirus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 12: Rate of monthly rotavirus-associated hospitalizations compared to all hospital admissions by year



Test positivity rate over time

We included 122,597 rotavirus lab results with a known result of which 2,764 were positive. The rotavirus test positivity rate is shown in Figure 13. Figure 14 shows yearly trends.

Figure 13: Monthly rotavirus test positivity rate since October 2019

Figure 15: Monthly rotavirus test positivity rate by year



Infants and children (age 0-4)

Our infants and children study population consists of 483 hospitalizations of 453 unique patients (Table 4).

Table 4: Infants and children patient characteristics by year.

	2019	2020	2021	2022	2023	2024	Overall
N	12 (100.00%)	23 (100.00%)	64 (100.00%)	114 (100.00%)	167 (100.00%)	73 (100.00%)	453 (100.00%)
Age Group							
< 6 months	n/a	n/a	13 (20.31%)	27 (23.68%)	29 (17.37%)	16 (21.92%)	95 (20.97%)
6 - <12 months	n/a	n/a	17 (26.56%)	19 (16.67%)	39 (23.35%)	17 (23.29%)	99 (21.85%)
1 - <2 years	n/a	n/a	19 (29.69%)	37 (32.46%)	44 (26.35%)	15 (20.55%)	126 (27.81%)
2 - 4 years	n/a	n/a	15 (23.44%)	31 (27.19%)	55 (32.93%)	25 (34.25%)	133 (29.36%)
Sex							
Female	n/a	n/a	23 (35.94%)	42 (36.84%)	72 (43.11%)	41 (56.16%)	187 (41.28%)
Male	n/a	17 (73.91%)	40 (62.50%)	71 (62.28%)	94 (56.29%)	32 (43.84%)	263 (58.06%)
Unknown	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Race							
White	n/a	n/a	24 (37.50%)	49 (42.98%)	89 (53.29%)	36 (49.32%)	213 (47.02%)
Black or African American	n/a	n/a	n/a	21 (18.42%)	21 (12.57%)	n/a	62 (13.69%)
Asian	n/a	n/a	n/a	n/a	10 (5.99%)	n/a	19 (4.19%)
Native Hawaiian or Other Pacific Islander	n/a	n/a	n/a	n/a	n/a	n/a	17 (3.75%)
American Indian or Alaska Native	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Race	n/a	n/a	29 (45.31%)	25 (21.93%)	25 (14.97%)	21 (28.77%)	109 (24.06%)
Declined to answer	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Unknown	n/a	n/a	n/a	n/a	n/a	n/a	23 (5.08%)
Ethnicity							
Hispanic or Latino	n/a	n/a	28 (43.75%)	31 (27.19%)	56 (33.53%)	31 (42.47%)	159 (35.10%)
Not Hispanic or Latino	n/a	14 (60.87%)	31 (48.44%)	72 (63.16%)	106 (63.47%)	38 (52.05%)	267 (58.94%)
Declined to answer	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Unknown	n/a	n/a	n/a	11 (9.65%)	n/a	n/a	25 (5.52%)
Virus							
norovirus	n/a	n/a	39 (60.94%)	69 (60.53%)	95 (56.89%)	34 (46.58%)	250 (55.19%)
rotavirus	n/a	14 (60.87%)	25 (39.06%)	45 (39.47%)	72 (43.11%)	39 (53.42%)	203 (44.81%)

Hospitalization rate over time

The rate of viral gastroenteritis-associated hospitalizations compared to all hospitalizations for infants and children under age five is shown in Figure 16. Figure 17 shows the same data stacked to represent the combined impact of the viruses.

Figure 16: Rate of monthly viral gastroenteritis-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under age five



Figure 17: Rate of monthly viral gastroenteritis-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under age five



Test positivity rate over time

We included 12,522 lab results with a known result of infants and children under age five. Of those tests, 1,564 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 18.

Figure 18: Monthly test positivity rate since October 2019 for infants and children under age five



Older adults (aged 65 and over)

Our older adults study population consists of 2,406 hospitalizations of 2,374 unique patients (Table 5).

Table 5: Older adults patient characteristics by year.

	2019	2020	2021	2022	2023	2024	Overall
N	70 (100.00%)	115 (100.00%)	186 (100.00%)	556 (100.00%)	976 (100.00%)	471 (100.00%)	2,374 (100.00%)
Age Group							
65 - 74 years	23 (32.86%)	43 (37.39%)	73 (39.25%)	242 (43.53%)	416 (42.62%)	170 (36.09%)	967 (40.73%)
75 - 84 years	32 (45.71%)	47 (40.87%)	78 (41.94%)	196 (35.25%)	359 (36.78%)	194 (41.19%)	906 (38.16%)
85+ years	15 (21.43%)	25 (21.74%)	35 (18.82%)	118 (21.22%)	201 (20.59%)	107 (22.72%)	501 (21.10%)
Sex							
Female	41 (58.57%)	69 (60.00%)	106 (56.99%)	315 (56.65%)	564 (57.79%)	269 (57.11%)	1,364 (57.46%)
Male	29 (41.43%)	46 (40.00%)	79 (42.47%)	240 (43.17%)	403 (41.29%)	199 (42.25%)	996 (41.95%)
Unknown	n/a	n/a	n/a	n/a	n/a	n/a	14 (0.59%)
Race							
White	64 (91.43%)	94 (81.74%)	159 (85.48%)	489 (87.95%)	816 (83.61%)	401 (85.14%)	2,023 (85.21%)
Black or African American	n/a	11 (9.57%)	18 (9.68%)	29 (5.22%)	52 (5.33%)	27 (5.73%)	139 (5.86%)
Asian	n/a	n/a	n/a	n/a	20 (2.05%)	n/a	32 (1.35%)
Native Hawaiian or Other Pacific Islander	n/a	n/a	n/a	n/a	n/a	n/a	n/a
American Indian or Alaska Native	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Race	n/a	n/a	n/a	26 (4.68%)	66 (6.76%)	26 (5.52%)	132 (5.56%)
Declined to answer	n/a	n/a	n/a	n/a	n/a	n/a	10 (0.42%)
Unknown	n/a	n/a	n/a	n/a	12 (1.23%)	n/a	28 (1.18%)
Ethnicity							
Hispanic or Latino	n/a	n/a	19 (10.22%)	38 (6.83%)	112 (11.48%)	42 (8.92%)	217 (9.14%)
Not Hispanic or Latino	67 (95.71%)	99 (86.09%)	159 (85.48%)	489 (87.95%)	828 (84.84%)	419 (88.96%)	2,061 (86.82%)
Declined to answer	n/a	n/a	n/a	n/a	n/a	n/a	11 (0.46%)
Unknown	n/a	10 (8.70%)	n/a	26 (4.68%)	32 (3.28%)	n/a	85 (3.58%)

Virus							
norovirus	66 (94.29%)	101 (87.83%)	156 (83.87%)	402 (72.30%)	799 (81.86%)	355 (75.37%)	1,879 (79.15%)
rotavirus	n/a	14 (12.17%)	30 (16.13%)	154 (27.70%)	177 (18.14%)	116 (24.63%)	495 (20.85%)

Hospitalization rate over time

The rate of viral gastroenteritis-associated hospitalizations compared to all hospitalizations for adults aged 65 and over is shown in Figure 19. Figure 20 shows the same data stacked to represent the combined impact of the viruses.

Figure 19: Rate of monthly viral gastroenteritis-associated hospitalizations compared to all hospital admissions since October 2019 for adults aged 65 years or older



Figure 20: Rate of monthly viral gastroenteritis-associated hospitalizations compared to all hospital admissions since October 2019 for adults aged 65 years or older



Test positivity rate over time

We included 97,635 lab results with a known result of adults 65 and over. Of those tests, 3,172 lab results were positive. The test positivity rate for adults 65 and over is shown in Figure 21.

Figure 19: Rate of monthly viral gastroenteritis-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Discussion and Conclusion

We see evidence that we are in the peak of the norovirus and rotavirus season. The overall timeseries trends of hospitalizations associated with these viruses show a steady increase over the last months, leading to a rate of 0.21% in April 2024 in the overall population. Similar trends can be observed in test positivity rates and the two high-risk sub populations: infants and children and older adults.

In the overall and adult over age 65 population, norovirus causes 2 to 3 times higher hospitalization rates than rotavirus. However, in the population of infants and children, both viruses have similar hospitalization rates. We will continue to monitor trends of norovirus- and rotavirus-associated hospitalizations and their test positivity.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed May 14, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a viral gastroenteritis who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor viral gastroenteritis-associated hospitalization overall and for the at-risk populations.

Suggested citation

Suggested citation: "Truveta Monitoring Report: Viral gastroenteritis, Truveta Inc. Truveta.com/research. Accessed on DATE".

References

Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, Koopmans M, Lopman BA. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014 Aug;14(8):725-730. doi: 10.1016/S1473-3099(14)70767-4. Epub 2014 Jun 26. PMID: 24981041; PMCID: PMC8006533.

Chhabra P, Payne DC, Szilagyi PG, Edwards KM, Staat MA, Shirley SH, Wikswo M, Nix WA, Lu X, Parashar UD, Vinjé J. Etiology of viral gastroenteritis in children <5 years of age in the United States, 2008-2009. J Infect Dis. 2013 Sep 1;208(5):790-800. doi: 10.1093/infdis/jit254. Epub 2013 Jun 10. PMID: 23757337.

Anderson, Evan J., and Stephen G. Weber. "Rotavirus infection in adults." The Lancet infectious diseases 4.2 (2004): 91-99.

Lopman B, Gastañaduy P, Park GW, Hall AJ, Parashar UD, Vinjé J. Environmental transmission of norovirus gastroenteritis. Curr Opin Virol. 2012 Feb;2(1):96-102. doi: 10.1016/j.coviro.2011.11.005. Epub 2011 Dec 11. PMID: 22440972.

Lopman BA, Hall AJ, Curns AT, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007. Clin Infect Dis. 2011 Feb 15;52(4):466-74. doi: 10.1093/cid/ciq163. Epub 2011 Jan 22. PMID: 21258098.

Troeger C, Khalil IA, Rao PC, et al. Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years. JAMA Pediatr. 2018;172(10):958-965. doi:10.1001/jamapediatrics.2018.1960

Centers for Disease Control and Prevention. (2023, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Truveta. (2022). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy